Thrombotic thrombocytopenic purpura (TTP) related to systemic lupus erythematosus may not cause worse outcomes compared with primary immune-mediated TTP.
A team of investigators evaluated knowledge gaps among patients with TTP in remission and found a range of levels of understanding of the condition.
TTP is a rare disease that clinicians may not often treat; however, it is important to be aware of new developments for the treatment of this patient population.
In patients hospitalized with COVID-19, thrombi in segmental pulmonary arteries are common and are located in opacitated lung segments, which may suggest local clot formation.
Among some patients with cancer-associated thrombosis, rivaroxaban may be a viable alternative to low-molecular-weight heparin.
A position paper recently published by the National Pulmonary Embolism Response Team outlines an approach for diagnosing and treating pulmonary embolism in patients with COVID-19.
Researchers sought to markers that could identify high risk for splanchnic vein thrombosis among patients with MPNs.
Eltrombopag may be an effective alternative to intravenous immunoglobulin for the perioperative treatment of immune thrombocytopenia.
Investigators assess underlying mechanisms and relevant biomarkers of morbidity and mortality due to coagulopathy in patients with severe COVID-19 infection.
Inadvertent administration may result in serious adverse events.
Increases in the incidence of CVT from 2006 to 2016 driven mainly by increases among men, older women.
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Researchers studied the effect of certain biomarkers on long-term adverse cardiovascular outcomes in patients with coronary morbidities undergoing PCI.
As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.
As PKD directly affects the catalysis of substrates and products involved in the production of ATP, the glycolytic pathway is compromised, thus leading to several cellular defects.
Investigators conducted a large case series of CMV-linked thrombocytopenia to highlight treatment and response in immunocompetent adults.
Investigators aimed to determine the outcomes and indications of cytoreductive treatment in patients with
CALR-positive essential thrombocythemia.
Although venous thromboembolism is a marker of mortality, it is not necessarily always the cause of death.
COVID-19 ICU patients exhibited distinct phenotypic traits that suggested standard VTE prophylaxis is insufficient in this population.
A prospective, single-center study aimed to determine the prevalence of DVT after TKA among patients with hemophilia A and found that contrast-enhanced CT led to better detection compared with ultrasound.
The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.
Caplacizumab appears to be safe and effective among patients with acquired thrombotic thrombocytopenic purpura treated in the real-world setting.
Although etiologies and traits of early and late thrombotic microangiopathy may vary, outcomes for both patient populations are similarly unfavorable.
Although the association between thrombocytosis in iron deficiency anemia is understood, researchers studied the risk for thrombotic complications.
In a number of COVID-19 autopsies, thrombosis of multiple organs was a prominent feature, regardless of timing of disease course and anticoagulation status.
Surface accumulation of parasite histones may be linked to coagulation activation and blood-brain barrier breakdown in children with cerebral malaria.
The British Society of Haematology released updates to 2 previous guidelines to help clinical laboratories with assays for coagulant diagnostic services.
The purpose of this study was to determine if a cytoreductive agent could provide additional efficacy to treat blood hyperviscosity.
VTE-BLEED prognostic scores did not accurately identify patients with VTE who were at high risk of bleeding events.
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.
Investigators developed an accurate prediction model for the early identification of refractory immune-mediated TTP.
Anagrelide, a platelet-lowering agent with US FDA approval and EMA licensing for the treatment of patients with ET, is associated with prolonged response to initial therapy.
It may be important to sequence
ETV6in patients with inherited thrombocytopenia or malignancy and to schedule regular follow-ups to check for secondary cancers.
Obesity in early adulthood is associated with increased risk for venous thromboembolism later in life, especially pulmonary embolism.
Replacing DOACs with alternative parenteral antithrombotic strategies may help to prevent bleeding complications in patients with SARS-CoV-2 infection.
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Longer duration of AC treatment linked to reduced risk for mortality in hospitalized patients.
Investigators compared the use of DOACs with traditional therapies in patients with acute VTE who were either discharged directly from the ED or hospitalized.
Investigators assessed rates of VTE and arterial thrombotic complications in patients admitted to the ICU with COVID-19 infection.
Case fatality rates may vary among cancer patients with VTE or major bleeding who receive anticoagulant treatments.
Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
Splenectomy may be a safe therapeutic options for children with nonmalignant hematologic diseases who have proper vaccinations and follow-up care.
Oral apixaban is noninferior to subcutaneous dalteparin for the treatment of cancer-linked VTE without increasing the risk of major bleeding.
Apixaban or rivaroxaban may be as safe and effective at treating upper extremity deep vein thrombosis as low molecular weight heparin and warfarin.
Prophylactic anticoagulation protocol improves patient outcomes.
Patients with idiopathic thrombocytopenic purpura may have a higher risk of systemic lupus erythematosus and should be monitored for incidental lupus.
Rivaroxaban superior to enoxaparin for preventing major VTE after nonmajor orthopedic surgery.
Compared with controls, the experimental mouse model group was less susceptible to arterial thrombosis in settings using ferric chloride and laser injury–induced thrombosis.
High or intermediate PE risk status was linked with lower rates of DVT, but asymptomatic DVT was more often found with high or intermediate PE risk.
The authors stated, however, that genetic screening should be used with caution in children.
The primary end point of increased platelet count was achieved by 13 of 18 patients with severe refractory immune thrombocytopenia.